Evidence map›Paper›PMID 41343125›Full record

Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026

Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial.

Ryohei Kawabata, Daisuke Sakai, Toshio Shimokawa, Rika Kizawa, Toru Ishiguro, Hiroki Yukami, Shogen Boku, Toshifumi Yamaguchi, Shunji Endo, Toshimasa Tsujinaka and 1 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ryohei KawabataOsaka Rosai Hospital, Sakai, Japan. r-kawabata@umin.ac.jp.ORCID 0000-0001-7386-1096
Daisuke SakaiThe University of Osaka Hospital, Suita, Japan.
Toshio ShimokawaWakayama Medical University, Wakayama, Japan.
Rika KizawaToranomon Hospital, Tokyo, Japan.
Toru IshiguroSaitama Medical Center, Saitama Medical University, Saitama, Japan.
Hiroki YukamiOsaka Medical and Pharmaceutical University, Osaka, Japan.
Shogen BokuKansai Medical University Hospital, Hirakata, Japan.
Toshifumi YamaguchiOsaka Medical and Pharmaceutical University, Osaka, Japan.
Shunji EndoKawasaki Medical School, Kurashiki, Japan.
Toshimasa TsujinakaIzumi City General Hospital, Osaka, Japan.
Taroh SatohThe University of Osaka Hospital, Suita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn late-line treatment for advanced gastric cancer (AGC), evidence supporting the use of irinotecan in older patients remains limited. We conducted a post-hoc age-subgroup analysis of the phase III RINDBeRG study, which randomized AGC patients previously treated with ramucirumab-based chemotherapy to receive ramucirumab plus irinotecan (RAM + IRI) or irinotecan alone (IRI).

methodsPatients were classified as elderly (≥ 70 years; n = 83 [RAM + IRI], 80 [IRI]) or non-elderly (< 70 years; n = 117, 113). Efficacy outcomes-including overall survival (OS), progression-free survival (PFS), and overall response rate (ORR)-and safety were compared. Prognostic factors for OS were explored via multivariable Cox regression.

resultsOS and PFS did not differ significantly between age groups. In the RAM + IRI group, median OS was 9.7 vs. 8.9 months (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.63-1.15), and PFS was 4.0 vs. 3.6 months (HR 0.84, CI 0.63-1.12). In the IRI group, OS was 8.5 months in both groups (HR 0.99, CI 0.7-1.34), and PFS was 3.1 vs. 2.2 months (HR 0.87, CI 0.65-1.17). ORRs were 20.5% vs. 14.5% (RAM + IRI) and 18.8% vs. 9.7% (IRI) in elderly vs. non-elderly patients. Grade ≥ 3 adverse events were comparable. Multivariable analysis identified ECOG PS 1, peritoneal metastasis, elevated LDH, modified Glasgow Prognostic Score ≥ 1, and low alkaline phosphatase as poor prognostic factors. Age was not prognostic.

conclusionsIrinotecan-based therapy offers comparable efficacy and tolerability in older and younger patients with refractory AGC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsIrinotecanStomach NeoplasmsAdultAgedAged, 80 and overAge FactorsAntibodies, Monoclonal, HumanizedFemaleHumansMaleMiddle AgedPrognosisProgression-Free SurvivalRamucirumabSurvival RateAntibodies, Monoclonal, HumanizedIrinotecanRamucirumabElderly patientsGastric cancerIrinotecan

Identifiers

PMID41343125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.